Mark Levy, Derivatively on Behalf of Immunogen Inc. v. Southbrook International Investments, Ltd. And Immunogen, Inc., Nominal-Defendant-Appellee

263 F.3d 10, 2001 U.S. App. LEXIS 19002, 2001 WL 958043
Court of Appeals for the Second Circuit·Decided August 23, 2001·No. 00-7630·Published·Cited by 130 cases

Opinion

PARKER, Circuit Judge:

Plaintiff-appellant, Mark Levy (“Levy”), is a shareholder of ImmunoGen, Inc (“Im-munoGen”). He brings this shareholder derivative action alleging that defendant, Southbrook International Investment, Ltd. (“Southbrook”), by virtue of its ownership of ImmunoGen convertible preferred shares, is a more than 10% beneficial owner of ImmunoGen common stock and realized short swing profits through the purchase and sale of ImmunoGen stock within a six month period. Plaintiff-appellant seeks disgorgement of Southbrook’s profits as required by Section 16(b) of the *12 Securities and Exchange Act of 1934 as amended, 15 U.S.C. § 78p(b) (“the Exchange Act”).

Article III, Paragraph 3.10 (“the conversion cap”) of the Convertible Preferred Stock Purchase Agreement between Im-munoGen and Southbrook (“the Agreement”) provides that Southbrook may not convert shares to the extent that such conversion would result in Southbrook owning more than 4.9% of ImmunoGen’s outstanding common stock.

There is no claim that Southbrook ever exceeded the conversion cap. Rather, plaintiff-appellant claims that due to Southbrook’s ability to make limited conversions and sales over a sixty-day period it could have cumulatively owned more than 10% of ImmunoGen’s common stock within the meaning of 17 C.F.R. § 240.13d-3(a) and 13d-3(d)(l)(i) (“Rules 13d-3(a) and 13d — 3(d)(l)(i),” respectively). Therefore, according to plaintiff-appellant, Southbrook is a more than 10% beneficial owner within the meaning of Section 16(b) and subject to Section 16(b) short-swing trading liability.

In the alternative, plaintiff-appellant contends that:

(1) the Agreement is void as a “sham transaction”; (2) the conversion limitation provision is void pursuant to 17 C.F.R. § 240.13d-3b (“Rule 13d-3(b)”); 1 and (3) the conversion limitation constitutes a waiver of section 16(b), and therefore is void pursuant to Section 29(a) of the Exchange Act as amended, 15 U.S.C. § 78cc(a). 2

Southbrook counters that, because the conversion cap prevents Southbrook from owning, at any one point, more than 4.9% of ImmunoGen’s common stock, South-brook is not a more than 10% beneficial owner within the meaning of Rules 13d-3(a) and 13d — 3(d)(l)(i), and consequently, is not subject to Section 16(b) short-swing trading liability. Additionally, according to Southbrook, because the conversion cap is valid and binding, plaintiff-appellant’s alternative grounds for relief are inapplicable.

We conclude that where a binding conversion cap denies an investor the right to acquire more than 10% of the underlying equity securities of an issuer, at any one time, the investor is not, by virtue of his or her ownership of convertible securities, the beneficial owner of more than 10% of those equity securities within the meaning of Rules 13d 3(a) and 13d-3(d)(l)(i). We further find that the conversion cap in this case is binding, and accordingly, affirm the decision of the district court.

I. BACKGROUND

The allegations in the complaint disclose the following. On October 16, 1996 South-brook and ImmunoGen entered into the Agreement. Pursuant to the agreement Southbrook agreed to purchase Immuno-gen convertible preferred stock. The *13 Agreement limits Southbrook’s ability to convert the preferred stock to the extent that such conversion would result in South-brook owning more than 4.9% of the common stock, at any one time. The conversion cap in part reads as follows:

3.10 Purchaser Ownership of Common Stock. The Purchaser may not use its ability to convert Shares hereunder or under the terms of the Vote Certificates or to exercise its right to acquire shares of common stock under the Warrants to the extent that such conversion or exercise would result in the Purchaser owning more than 4.9% of the outstanding shares of the Common Stock.

Joint App. at 36 (Convertible Preferred Stock Purchase Agreement, ¶ 3.10).

Plaintiff-appellant alleges that by February 21, 1997, Southbrook was a more than 10% beneficial owner of Immuno-Gen’s outstanding common stock by virtue of Southbrook’s ownership of ImmunoGen convertible preferred stock. The complaint further alleges that between January 1 and February 4, 1997, Southbrook acquired ImmunoGen common shares through conversion and sold them presumably at a profit. Southbrook allegedly repeated this process between January 27 and August 4, 1997, and again in October 1997.

On December 28, 1998, plaintiff-appellant demanded that ImmunoGen’s Board of Directors bring an action to cause, Southbrook to disgorge its alleged, short swing profits. See Levy v. Southbrook International Investments, Ltd., No. 99 Civ. 1480 NRB, 2000 WL 567008, at *2 (S.D.N.Y. May 10, 2000). By letter dated February 18, 1999, the Board refused, and this suit followed. See id.

Plaintiff-appellant, Mark Levy, derivatively on behalf of ImmunoGen, brought this action for disgorgement pursuant to Section 16(b) of the Exchange Act, claiming that Southbrook improperly profited from its investment in ImmunoGen because it was a more than 10% beneficial owner of ImmunoGen’s common stock. See id. at *1. Southbrook filed a motion to dismiss pursuant to Fed.R.Civ.P. 12(b)(6), for failure to state a claim, on the ground that the conversion cap prevented it from being a more than 10% beneficial owner of ImmunoGen common stock. See id. Southbrook’s motion to dismiss was accompanied by an affidavit and copies of various documents referred to in the complaint. 3

The district court, in a written opinion, granted Southbrook’s motion to dismiss. See id. It found plaintiff-appellant’s beneficial ownership argument inconsistent with precedent in this Circuit. See id. (citing Levner v. Saud, 903 F.Supp. 452 (S.D.N.Y.1994), aff'd, Levner v. Prince Alwaleed, 61 F.3d 8 (2d Cir.1995)). Additionally, the district court concluded that “it is clear that only those holders of derivative securities, who could acquire ownership, by conversion or otherwise, of more than 10% of the common stock, at one time, are subject to § 16(b) liability.” Id. at *10 (emphasis in original).

Free access — add to your briefcase to read the full text and ask questions with AI

Mark Levy, Derivatively on Behalf of Immunogen Inc. v. Southbrook International Investments, Ltd. And Immunogen, Inc., Nominal-Defendant-Appellee, 263 F.3d 10, 2001 U.S. App. LEXIS 19002, 2001 WL 958043 (2d Cir. 2001).

263 F.3d 10 (Mark Levy, Derivatively on Behalf of Immunogen Inc. v. Southbrook International Investments, Ltd. And Immunogen, Inc., Nominal-Defendant-Appellee) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

DiMuro v. Clinique Laboratories, LLC
572 F. App'x 27 (Second Circuit, 2014)
Lowinger v. Morgan Stanley & Co. LLC
986 F. Supp. 2d 544 (S.D. New York, 2014)
Donoghue v. Patterson Companies, Inc.
990 F. Supp. 2d 421 (S.D. New York, 2013)
Kivo v. Blumberg Exelsior, Inc.
982 F. Supp. 2d 217 (E.D. New York, 2013)
Vallejo Sanitation & Flood Control District v. Fuld
903 F. Supp. 2d 152 (S.D. New York, 2012)
Fattoruso v. Hilton Grand Vacations Co.
873 F. Supp. 2d 569 (S.D. New York, 2012)
In Re Lehman Bros. Securities and Erisa Litigation
799 F. Supp. 2d 258 (S.D. New York, 2011)
Facebook, Inc. v. Pacific Northwest Software, Inc.
640 F.3d 1034 (Ninth Circuit, 2011)
Elliott Associates v. Porsche Automobil Holding SE
759 F. Supp. 2d 469 (S.D. New York, 2010)
United States Ex Rel. Pervez v. Beth Israel Medical Center
736 F. Supp. 2d 804 (S.D. New York, 2010)
In Re IndyMac Mortgage-Backed Securities Litigation
718 F. Supp. 2d 495 (S.D. New York, 2010)
Fait v. Regions Financial Corp.
712 F. Supp. 2d 117 (S.D. New York, 2010)
Tsereteli v. Residential Asset Securitization Trust 2006-A8
692 F. Supp. 2d 387 (S.D. New York, 2010)